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Abstract Overexpression of urokinase-type plasminogen
activator receptors (uPAR) represents an important bio-
marker for aggressiveness in most common malignant
diseases, including prostate cancer (PC). Accordingly,
uPAR expression either assessed directly in malignant PC
tissue or assessed directly in plasma (intact/cleaved
forms)—provides independent additional clinical informa-
tion to that contributed by PSA, Gleason score, and other
relevant pathological and clinical parameters. In this
respect, non-invasive molecular imaging by positron
emission tomography (PET) offers a very attractive tech-
nology platform, which can provide the required quanti-
tative information on the uPAR expression profile, without
the need for invasive procedures and the risk of missing the
target due to tumor heterogeneity. These observations
support non-invasive PET imaging of uPAR in PC as a
clinically relevant diagnostic and prognostic imaging
method. In this review, we will focus on the recent
development of uPAR PET and the relevance within
prostate cancer imaging. Novel antibody and small-mole-
cule radiotracers-targeting uPAR, including a series of
uPAR-targeting PET ligands, based on the high affinity
peptide ligand AE105, have been synthesized and tested
in vitro and in vivo in preclinical murine xenograft models
and, recently, in a first-ever clinical uPAR PET study in
cancer patients, including patients with PC. In this phase I
study, a high and specific uptake of the tracer 64Cu-DOTA-
AE105 was found in both primary tumors and lymph node
metastases. The results are encouraging and support large-
scale clinical trials to determine the utility of uPAR PET in
the management of patients with PC with the goal of
improving outcome.
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Introduction
Prostate cancer (PC) is the most commonly diagnosed
cancer amongst men in western countries [1]. The prognosis
of PC is highly variable, with some PCs remaining latent
disease not causing any clinical symptoms or morbidity,
whereas other PCs are aggressive and associated with fast
progression and high mortality [1, 2]. Due to limitations of
the currently available diagnostic and prognostic tools,
over-diagnosis and unnecessary treatment of indolent dis-
ease are a major issue, and novel diagnostic and/or prog-
nostic biomarkers for PC are urgently needed [1, 3].
New sophisticated molecular imaging modalities with
multiparametric magnetic resonance imaging (mpMRI)
and positron emission tomography (PET) using 18F-fluoro-
deoxy-glucose (FDG), radiolabeled choline, and alternative
radioligands, such as gastrin-releasing peptide receptor
(GRPR)-targeting ligand and prostate-specific membrane
antigen (PSMA)-targeting ligand, are currently investi-
gated for all aspects of PC, including diagnosis and
localization, staging, active surveillance, prognosis, and
monitoring recurrence [1].
D. Skovgaard, M. Persson, and A. Kjaer authors contributed equally
to this work.
& Andreas Kjaer
akjaer@sund.ku.dk
1 Department of Clinical Physiology, Nuclear Medicine &
PET and Cluster for Molecular Imaging, Rigshospitalet and
University of Copenhagen, National University Hospital,
Blegdamsvej 9, 2100 Copenhagen, Denmark
2 Curasight, Copenhagen, Denmark
123
Clin Transl Imaging (2016) 4:457–465
DOI 10.1007/s40336-016-0197-4
In this review, we will focus on PET imaging of a new
promising molecular target; urokinase-type plasminogen
activator receptor (uPAR) in PC as a clinically relevant
diagnostic and prognostic imaging biomarker with the
possibility of distinguishing indolent tumors from the
invasive phenotype. The majority of references for this
review were found by searching PubMed for ‘‘uPAR’’,
‘‘urokinase-type plasminogen activator receptor’’, ‘‘pros-
tate cancer’’, and ‘PET’ or ‘positron emission tomography’.
Additional references were also incorporated on the basis
of the author’s experience in basic research within uPAR or
related fields as well as by cross-referencing.
uPAR and the aggressive phenotype
The urokinase plasminogen activator (PA) system plays a
key role in the pericellular proteolytic activity which is
required for tissue remodeling during normal physiological
conditions, such as wound healing and initiation of
angiogenesis, but also in pathophysiologically processes,
such as cancer invasion [2–7] (Fig. 1). The PA system
consists of the serine protease urokinase-type plasminogen
(uPA), its glycosylphosphatidylinositol (GPI)-anchored
cell membrane receptor (uPAR), and two specific inhibitors
PAI-1 and PAI-2. uPA binds with high affinity to uPAR
and, consequently, converts plasminogen to active plasmin,
which activates several proteases related to the degradation
of extracellular matrix proteins and basal membranes,
thereby facilitating cancer cell invasion and metastasis [8].
It has become increasingly clear that PA not only is central
in proteolytic degradation of extracellular matrix but also
affects multiple other aspects of the tumor progression and
development by eliciting tumor-associated processes, such
as cell proliferation, cell adhesion and migration, chemo-
taxis, and cell survival through interactions with co-re-
ceptors to relay intracellular downstream signaling
pathways. Integrins, G-protein-coupled receptors, and
Fig. 1 Schematic overview of the uPA/uPAR system. Urokinase-
type plasminogen activator receptor (uPAR) is tethered to the cell
membrane with a glycosylphosphatidylinositol (GPI) anchor and
binds the protease urokinase-type plasminogen activator (uPA). uPA
cleaves plasminogen, generating the active protease plasmin. Plasmin
cleaves and activates matrix metalloproteases (MMPs). Both plasmin
and MMPs degrade many extracellular matrix (ECM) components
and thereby promote cancer invasion and metastasis. The proteolytic
activities of uPA and plasmin are inhibited by PAI1, PAI2, and a2-
antiplasmin. When uPA is bound to uPAR, there is cleavage between
the GPI-anchor and the uPAR, releasing suPAR into the vascular
system, and uPA also cleaves uPAR in the linker between its first and
second domains (D1 and D2), generating a soluble D1 fragment and a
membrane-associated D2–D3 fragment
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growth factor receptors are found to directly interact with
uPAR, and are assumed to serve as co-receptors for uPAR-
mediated PAR-mediated downstream signaling and/or
activation pathways [9].
Using various biochemical assays; immunohistochem-
istry (IHC), tissue micro-arrays, and reverse transcriptase-
polymerase chain reactions (PCR), uPAR expression can
be assessed directly in tumor specimens and is particularly
high in cancer cells at the very front of the invasive tumor
as well as in tumor-associated stromal cells, such as
fibroblasts and macrophages [10–12]. High-tumor expres-
sion of uPAR has shown to predict adverse outcome in a
wide variety of malignancies, including breast, colorectal,
pancreatic, and PC [5].
In addition, uPAR can be cleaved from the membrane,
and high levels of soluble uPAR and/or various uPAR
forms in the blood have been reported in a number of
cancers. Intact uPAR(I–III) can be cleaved by uPA,
releasing domain I [uPAR(I)], while leaving uPAR(II–III)
on the cell surface. Both of the glycolipid-anchored uPAR
forms [uPAR(II–III) and uPAR(I–III)] can be shed from
the cell membrane, resulting in three soluble uPAR forms
[uPAR(I–III) and uPAR(II–III) as well as uPAR(I)]
detectable in the blood [13]. Interestingly, the cleaved
soluble uPAR forms have been demonstrated to be inde-
pendent prognostic markers in various types of cancer [14],
such as colorectal [15, 16], breast [17], lung [18], and PC
[19]. However, measurement of plasma levels of uPAR
(intact/cleaved domains) will always only be an indirect
indicator for the expression level in the tumor. Moreover,
the lack of correlation between tumor tissue uPAR
expression and the level of secreted different forms of
uPAR [20], together with the fact, the majority of cancer
patients have uPAR levels within the reference interval of
healthy individuals [21], further complicate the information
achievable. This is, perhaps, the main reason for the lack of
routine clinical use of plasma uPAR measurements. It
seems that localized measurements, encompassing the
heterogeneity, in the tumor and in the local microenvi-
ronment, are necessary for optimal uPAR-based diagnostic
and prognostic information.
uPAR and prostate cancer
Compared to other malignant diseases, such as breast can-
cer and colorectal cancer, the role of uPAR expression in
PC is less well investigated and the majority of studies are
based on relatively small patient populations (\200
patients) focusing on blood levels of either intact or cleaved
forms of uPAR. Indeed, only few studies have attempted to
measure expression of uPAR directly in prostate tumor
specimens using the established biochemical techniques.
In general, uPAR IHC on PC tissue (biopsies or surgical
specimens) has demonstrated increased uPAR expression
in PC [22–25]. Examples of such studies include the use of
standard IHC on tissue micro-arrays, where Cozzi et al.
[25] found uPAR overexpression in primary PC cells,
surrounding tumor-associated stromal cells and lymph
node metastases, but not in normal prostate tissue. uPAR
expression was highly related to disease progression and
tumor differentiation, including Gleason score. An associ-
ation between high uPAR detected by IHC and relevant
pathological and clinical parameters, such as high Gleason
score, advanced tumor stage, positive lymph node status,
and incomplete tumor resection has also been confirmed in
other studies [24, 26]. However, in the study by Cozzi et al.
[25] and in a more recent study by Gupta et al. [26], no
difference in biochemical free survival was demonstrated,
possibly explained by short follow-up with only few
patients experiencing biochemical progression. Impor-
tantly, others have successfully found significant impact of
uPAR valuated by IHC staining of tumor specimens, on the
prognosis of PC patients [24].
Similar to the immunohistochemical analysis, uPAR
expression at mRNA level has only been investigated in a
limited number of studies and only in small populations of
PC patients, using either in situ hybridization or real-time
quantitative PCR (qPCR) [22, 23, 27, 28]. Riddick et al.
[28] used qPCR and found increased mRNA expression in
malignant tissue samples from patients with PC compared
to non-malignant samples from patients with benign pro-
static hyperplasia with statistically significant positive
correlations with Gleason score. However, this could not be
confirmed in the study by Al-Jabani et al. [27], where
increased mRNA expression levels of uPA and PAI-1 and
not uPAR were found in PC tissue compared to benign
prostate hyperplasia and normal prostate tissue.
As already mentioned, the majority of studies investi-
gating implications of uPAR in PC diagnosis and prognosis
have focused on the assessment of circulating soluble uPAR.
In line with this, serum from patients with PC contains
elevated levels of soluble uPAR compared with patients
with benign prostatic hypertrophy and healthy controls [29].
In addition, pre-operative circulating total uPAR levels were
found to be higher among patients with higher biopsy
Gleason grade, extraprostatic extension, and lymph node
positive disease after radical prostatectomy, and, indeed, PC
patients with bone metastasis exhibited significantly higher
uPAR levels compared with patients with localized disease
or patients with lymph node metastasis [30]. Furthermore,
studies have found significantly lowered overall survival
rate of PC patients with high plasma levels of uPAR com-
pared with low serum uPAR levels [27, 29]. In the most
recently published study, the plasma levels of the cleaved
uPAR forms, uPAR(I–III) ? uPAR(II–III) and
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uPAR(I) levels, were significantly higher, while level of
intact uPAR(I–III) did not differ, in hormone-naive and
castrate-resistant patients compared with patients with
localized disease, highlighting that analysis of the cleaved
forms might be superior and, thus, provide additional
prognostic and predictive information [31].
Although no definite conclusion can be drawn, the
majority of studies, although based on relatively small
populations, find uPAR expression, either assessed directly
in the malignant PC tissue or in plasma (intact/cleaved
forms), to be a largely independent analytical variable,
conceivably offering clinical information that is different
from and additive to that contributed by PSA, Gleason
score, and other relevant pathological/clinical parameters.
These observations highlight and support that non-invasive
imaging of uPAR in PC, with the possibility of distin-
guishing indolent tumors from the invasive phenotype,
could become a clinically relevant diagnostic and prog-
nostic imaging biomarker, as also identified by different
authors [6, 32].
uPAR PET imaging
One of the major challenges when assessing uPAR
expression directly in tumor specimen is intra-tumor
heterogeneity. This is of special importance in PC, which is
recognized as often being multifocal disease with a broad
spectrum of clinical, pathologic, and molecular character-
istics, emphasized by the routinely used 12-core biopsy
protocol for diagnosis of PC [33]. In this respect, non-
invasive molecular imaging by PET offers a very attractive
technology platform, which can provide the required
information on the global expression profile or function of
the target, such as uPAR, without the need for invasive
procedures [3] and the risk of missing the target due to
tumor heterogeneity.
Detailed insight into the molecular basis underlying the
interactions between uPAR and its ligand uPA has been
obtained by X-ray crystallography and surface plasmon
resonance studies. Importantly, these structural studies also
defined possible target sites in uPAR for small molecules,
which have led the development of a series of small pep-
tides applicable for non-invasive molecular imaging of
uPAR expression in vivo by positron emission tomography
[34].
In a uPAR PET proof-of-concept study [35], one of
these peptides, AE105 [36], conjugated with the metal
chelator DOTA in the N-terminal and labeled with 64Cu
was used. MicroPET imaging of mice-bearing uPAR-pos-
itive U87MG human glioblastoma and uPAR-negative
MDA-MB-435 human breast cancer xenografts was used to
illustrate the ability to specifically detect human uPAR. A
high accumulation in the uPAR-positive U87MG xenograft
tumor (10.8 ± 1.5 % ID per g) compared with the uPAR-
negative MDA-MB-435 xenograft tumor (1.2 ± 0.6 %
ID per g) was found 4.5 h after injection. The specificity of
the tracer was further validated by comparing the uptake of
a non-binding variant of the peptide in the uPAR-positive
U87MG xenograft and by performing a blocking experi-
ment using excessive pre-dose of non-labeled peptide
resulting in reduced tumor uptake, thus illustrating the
specificity of 64Cu-DOTA-AE105 for non-invasive PET
imaging of uPAR [35].
In our group, the focus has also been on AE105 in our
efforts to develop a uPAR-targeting PET ligand. We have
investigated the use of different metal-binding chelators
and different isotopes, including 64Cu, 68Ga, and 18F
[4, 37–40] (Fig. 2). Importantly, in our first experience, we
found a significant correlation between tumor uptake of
64Cu-DOTA-AE105 on microPET images of human tumor
xenografts and uPAR expression level in the tumor tissue
[37]. However, our results also revealed a relatively high
accumulation of 64Cu in the liver, a known site for 64Cu
accumulation, and a well-established indirect marker of
instability of 64Cu-based ligands in rodents [41, 42].
Therefore, two improved metal chelators (64Cu-CB-TE2A-
AE105 and 64Cu-CB-TE2A-PA-AE105) based on cross-
bridge cyclam N-conjugated to the AE105 were developed
and tested both in vitro and in vivo in preclinical mice
cancer models. In particular, 64Cu-CB-TE2A-PA-AE105
exhibited an improved tumor-to-liver ratio. In line with this
and based on the fast tumor uptake observed in our study,
we hypothesized that the use of 68Ga instead of 64Cu could
maintain tumor uptake and reduce the non-specific uptake
in non-target tissue, especially the liver. Furthermore, the
half-life of 68Ga more resembles the biological half-life of
our peptide-based ligand, and as 68Ga is a generator-based
radionuclide, this could make our ligand more widely used
in PET centers. The results of using 68Ga showed a sig-
nificant reduction in liver uptake as expected for both 68Ga-
DOTA-AE105 and 68Ga-NODAGA-AE105 [38]. How-
ever, this reduction was also accompanied by a reduction in
tumor uptake and a lower tumor-to-kidney ratio, compared
with 64Cu-DOTA-AE105. Later, we tested 18F-labeled
uPAR PET ligand, 18F-AlF-NOTA-AE105, and effectively
visualized non-invasively uPAR-positive PC in mice
models with high tumor-to-background ratio. Ex vivo
uPAR expression analysis on extracted tumors confirmed
human uPAR expression that correlated close with tumor
uptake of 18F-AlF-NOTA-AE105. In our latest effort to
develop a clinical uPAR PET ligand, 64Cu-NOTA-AE105
and 68Ga-NOTA-AE105 were developed and investigated
in a human orthotopic glioblastoma model in mice [40].
Again, uPAR expression levels correlated with uPAR
radiotracer uptake in resected glioblastoma tumors.
460 Clin Transl Imaging (2016) 4:457–465
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uPAR PET imaging in patients with PC
As the first step towards clinical translation of uPAR PET
imaging, we have conducted and reported the first-in-humans
trial of 64Cu-DOTA-AE105 (ClinicalTrials.gov:
NCT02139371). By definition, the primary endpoints of a
phase I clinical study are safety, biodistribution, and
dosimetry assessment based on three successive PET scans
performed at 1, 3, and 24 h post injection. We included total
of ten patients with urinary bladder (three patients), breast
(three patients), and prostate cancer (four patients). Impor-
tantly, no adverse events or clinically detectable pharmaco-
logic effects were found. Radiation dosimetry analysis
estimated an effective dose of 0.0276 mSv/MBq, closely
resembling the predicted effective dose from our previous
mouse study [43], and equaling 5.5 mSv for a 200 MBq
dose, which is lower/comparable radiation dose to the dose
received from a standard FDG-PET [44]. Secondary objec-
tives were to investigate the uptake in primary tumor lesions
and potential metastases. Four patients with newly diagnosed
and biopsy-proven PC (mean age 68, Gleason score 7–9)
were uPAR PET scanned prior to surgical pelvic lym-
phadenonectomy for staging and prostatectomy if indicated.
In all four patients, a high and specific uptake in the primary
intraprostatic lesion was found (Fig. 3). Histopathological
examination of three available surgical specimens confirmed
a general pattern of uPAR expression in the primary tumor,
supporting target-specific uptake of 64Cu-DOTA-AE105.
One patient had several visible uPAR PET positive lymph
nodes in the pelvic region, which was confirmed during the
staging operation and the following histopathological
assessment confirmed prostate adenocarcinoma in three out
of six removed lymph nodes (Fig. 3). Two patients had no
signs of metastases on neither uPAR PET nor perioperative
staging, while the last patient was found to have a metastasis
in 1 out of 17 regional lymph nodes that were not visualized
on uPAR PET or CT. The results of this phase I study was
encouraging with uPAR PET being able to identify both
primary tumors and lymph node metastases in PC, although
the limited number of patients precludes an evaluation of
uPAR PET in the initial staging of PC. We have recently
conducted another new phase I study, where safety, phar-
macokinetics and dosimetry of a 68Ga-labeled version of
AE105 (68Ga-NOTA-AE105) are being investigated in can-
cer patients (ClinicalTrials.gov: NCT02437539), and data
are currently under evaluation.
Fig. 2 uPAR PET imaging of small metastatic lesions. In a mouse
model of disseminated human prostate cancer and in this mouse
model of disseminated prostate cancer, C-3 M-LUC2 cells are
inoculated by intracardiac injection to mimic intravascular dissem-
ination and subsequent systemic establishment of metastatic disease.
As the PC-3 M-LUC2 cell-line is stably transfected with luciferase,
the formation of small metastatic lesions can be followed with
bioluminecence imaging (BLI). By comparison all tumors, lesions
identified on BLI scanning were also identified on uPAR PET on day
31 post initiation. Arrows indicate metastatic lesions with clearly
visualized uptake of 64Cu-DOTA-AE105 and unspecific uptake of
64Cu in the liver Adapted with permission from [48]. Copyright 2014
American Chemical Society
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Future directions
PET imaging of uPAR expression seems to be highly
promising and several important clinical questions in both
primary and metastatic PC can potentially be addressed
using uPAR PET.
In the diagnostic work up of patients suspected of PC,
various imaging techniques have been suggested to
enhance detection and localization of intraprostatic tumors
[1]. The current guideline with transrectal/perineal core
needle biopsies has a false negative rate of 20–25 % [45],
and it is suggested that the use of specific molecular
imaging might be helpful in image-guided biopsies, espe-
cially in patients with the previous negative findings [46].
However, since overtreatment is a big issue in localized
PC, a huge clinical potential lies in the possibility of dis-
tinguishing indolent tumors from the invasive phenotype
[44]. As noted above, uPAR expression correlates with PC
aggressiveness. As such, it could be expected that with a
quantitative imaging modality, such as PET, the degree of
radiotracer uptake might correlate with pathological and
clinical parameters, e.g., Gleason score and prognosis.
Clinically, significant disease that would benefit from
aggressive therapy with prostatectomy or radiotherapy
instead of watchful-waiting could potentially be non-in-
vasively identified by uPAR PET imaging.
Another important clinical implication of uPAR PET is
pre-operative staging. The ability of uPAR PET to pre-
operatively identify pelvic lymph node involvement in
high-risk primary PC will have to be investigated in well-
designed prospective studies. In addition, uPAR PET can
be applied in the context of biochemical recurrence fol-
lowing failed local therapy (usually detected as a rise in
serum PSA level). In these patients, a sensitive and reliable
imaging assessment for the localization of the site of
recurrent disease would potentially provide more appro-
priate guidance of treatment. Especially, in this indication,
it will be relevant to perform a head-to-head comparison
with the PSMA-targeting ligands that, in the recent years,
have found widespread use in biochemical recurrence due
to higher sensitivity than any other modality for relapse
localization.
In addition, targeting of uPAR with a monoclonal anti-
body blocking the biologic functions of uPAR was,
recently, shown to have a potent and encouraging thera-
peutic effect in murine prostate cancer models, including
bone metastases formation [47]. A non-invasive method for
specific assessment of tumor uPAR expression status
Fig. 3 uPAR PET imaging of patients with newly diagnosed prostate
cancer. Representative transverse CT, PET, and co-registered PET/
CT images from the first-ever uPAR PET study in humans. Upper
panel shows a primary tumor lesion (blue arrow) with high uptake of
64Cu-DOTA-AE105. uPAR immunohistochemistry on surgically
removed prostate cancer tissue confirmed general pattern of uPAR
expression. Bottom images show a uPAR-positive regional lymph
node metastasis (blue arrow) with high 64Cu-DOTA-AE105 uptake.
The subsequent staging operation and histopathological assessment
confirmed prostate adenocarcinoma in three out of six removed lymph
nodes. Reproduced from [44] with permission
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would be valuable. Such a tool would be clinically relevant
for the guidance of patient management and as companion
diagnostics for emerging uPAR-targeting therapies.
An innovative and interesting perspective is to combine
non-invasive PET imaging and targeted radionuclide therapy
in the management of metastatic PC. In this setting, the same
targeting ligand is radiolabeled with either a positron-emit-
ting nuclide for PET imaging or an alpha/beta-emitter nuclide
for therapeutic intervention. Such a dual functionality aligns
excellently with the concept of personalized medicine [48].
Targeted radiotherapy has shown promising results in several
cancers, with somatostatin receptor-based targeting of neu-
roendocrine tumors being the most successful so far [49], but
also recently applied in PC with 223Ra (ZofigoTM), an alpha-
emitter, for treatment of bone-related pain in castration-re-
sistant PC with bone metastases [50]. In fact, we have con-
ducted two preclinical proof-of-concept studies with DOTA-
AE105 conjugated with the beta-emitter 177Lu for uPAR-
targeted radionuclide therapy in colorectal cancer [51] and in
metastatic PC [48]. In metastatic PC (Fig. 4), we found a
significant reduction in metastatic lesions and longer overall
metastatic-free survival in mice treated with 177Lu-DOTA-
AE105 compared to controls, thus setting the stage for a
uPAR-mediated theranostic approach [48].
Conclusion
Due to the importance in cancer invasion and metastatic
development, uPAR is an attractive molecular target for
non-invasive PET imaging in PC with the possibility of
becoming a clinically relevant diagnostic and prognostic
imaging biomarker. Several versions of uPAR-targeting
PET ligands based on the high affinity peptide ligand
AE105 have been synthesized and tested preclinically in
human xenograft mouse models and, recently, also in a first-
ever clinical uPAR PET study in humans that included also
patients with PC. The clinical results, so far, are limited, but
encouraging and support large-scale clinical trials to
determine the utility of uPAR PET in the management of
patients with PC with the goal of improving outcome.
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